Evidence for operative treatment of talar osteochondral lesions: a systematic review

Helen Anwander, Philipp Vetter, Christophe Kurze, Chui J Farn, and Fabian G Krause

1Department of Orthopaedic Surgery and Traumatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
2Department of Orthopedic Surgery, National Taiwan University Hospital, Taiwan, Republic of China

• Purpose: Operative treatment of talar osteochondral lesions is challenging with various treatment options. The aims were (i) to compare patient populations between the different treatment options in terms of demographic data and lesion size and (ii) to correlate the outcome with demographic parameters and preoperative scores.
• Methods: A systemic review was conducted according to the PRISMA guidelines. The electronic databases Pubmed (MEDLINE) and Embase were screened for reports with the following inclusion criteria: minimum 2-year follow-up after operative treatment of a talar osteochondral lesion in at least ten adult patients and published between 2000 and 2020.
• Results: Forty-five papers were included. Small lesions were treated using BMS, while large lesions with ACI. There was no difference in age between the treatment groups. There was a correlation between preoperative American Orthopaedic Foot and Ankle Society (AOFAS) score and change in AOFAS score \( R=−0.849, P<0.001 \) as well as AOFAS score at follow-up \( R=0.421, P=0.008 \). Preoperative size of the cartilage lesion correlates with preoperative AOFAS scores \( R=−0.634, P=0.001 \) and with change in AOFAS score \( R=0.656, P<0.001 \) but not with AOFAS score at follow-up. Due to the heterogeneity of the studies, a comparison of the outcome between the different operative techniques was not possible.
• Conclusion: Patient groups with bigger lesions and inferior preoperative scores did improve the most after surgery.
• Level of evidence: IV.

Introduction

An osteochondral lesion of the talus (OLT) is defined as damage to the talar cartilage with pathological changes in the underlying bone. OLTs are associated with residual pain following an acute ankle sprain or in patients with chronic ankle instability. It has been shown that mainly the physical component of patients’ quality of life is impacted by an OLT (1). Untreated, an ankle with OLT may predispose to progressive degeneration of the entire joint. Primary management of OLT is conservative treatment including restriction of physical activity, weight-bearing, physiotherapy and orthopedic insoles to distribute the load in the ankle joint properly. The conservative treatment of symptomatic OLT achieves a success rate of 50% (2, 3). Numerous invasive therapies have been described; however, consensus particularly for bigger lesions has yet to be found (4).

The first operative treatment introduced was the sole debridement of unstable cartilage. Today, bone marrow stimulation (BMS) (i.e. microfracture and drilling) is the most common technique to stimulate fibrocartilage differentiation in the ankle with OLT up to 1–1.5 cm² in size. BMS can be supported by applying additional material such as hyaluronic acid. The sealing of the defect with a collagen matrix after BMS describes the technique of autologous matrix-induced chondrogenesis (AMIC) (6).

Autologous chondrocyte implantation (ACI) (7) is a two-step procedure. Initially, healthy cartilage is sampled from a non-weight-bearing area, mainly in the knee joint. Chondrocytes are grown in vitro for several weeks and, in a second surgery, implanted into the talar defect and covered with peristeam or a biomembrane. In matrix-induced ACI (MACI), the chondrocytes are placed on a membrane in the laboratory and this membrane with the chondrocytes attached to it is placed into the
defect. In contrast to fibrocartilage after BMS, the ACI and MACI techniques lead to the growth of hyaline-like cartilage. Bone marrow contains mesenchymal stem cells; subsequently, application of bone marrow aspirate has been proposed to provide hyaline-like cartilage.

In OLT with a cyst or too big for BMS, osteochondral autologous transplantation surgery (OATS) (8) has been introduced. OATS describes the transplantation of osteochondral cylinders (mainly from the knee) into the talar lesion. However, ACI, MACI and OATS come with a donor site morbidity in a before healthy knee joint. To minimize this disadvantage, osteo-periostal autograft and allograft have been introduced for the treatment of big OLTs. As gold standard treatment of OLT has yet to be found, the experimental techniques are constantly introduced.

The objective of this review is to compare the indications and effectiveness of all reported operative treatment options for OLTs in the adult population.

The first aim was to compare patient populations between the different treatment options in terms of demographic data and lesion size. The second aim was to correlate the outcome with demographic parameters and preoperative scores.

Our first hypothesis is that BMS was used for smaller lesions and OATS for bigger lesions compared to other treatment options. Our second hypothesis is that young patients with small lesions have a superior outcome than older patients with bigger lesions.

Methods

This is a systematic review conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The checklist as published by Page et al. was used (9). There was no funding for this study.

Literature research

The systematic review was conducted as follows: Electronic databases Pubmed (MEDLINE) and Embase were screened for reports published between January 2000 to December 2020. Additionally, a backward citation chaining strategy was applied.

The following keywords were included for the search: (Talus OR talus OR talar* OR ankle) AND (Osteochondritis Dissecans OR Osteochondritis dissecans OR osteochondrosis dissecans OR osteochondrolysis OR OCL OR OCD OR OLT OR osteochondral OR chondral OR transchondral OR cartilage*) AND (defect* OR lesion*). After the removal of duplications, this search resulted in 1653 records.

Selection criteria

Inclusion criteria were a randomized controlled trial (RCT) or an observational study assessing the outcome after operative treatment for OLT in a study group of at least ten patients aged 16 years and older. Twenty-four months represent the minimum maturation time for the newly formed cartilage tissue (10); subsequently, we chose 2 years as minimum follow-up. Operative treatment included arthroscopic as well as open cartilage treatment. One rationale to exclude case series with less than ten patients and studies with only a short-time follow-up was to exclude papers of low quality.

However, we did include studies with level of evidence I–IV and low methodological quality. The rationale to not conduct a level I meta-analysis is based on the available research around OLT with only sparse high-level evidence. Exclusion criteria were the following: text in a language other than English, no full text available and any other publication status than published.

Independent search and evaluation of the articles was conducted by two reviewers (HA and PV). In case of disagreement, the senior author made the decision which paper can be included. Studies were not blinded for author, affiliation or source. The literature selection algorithm is presented according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) (Fig. 1) (11).

Figure 1

Flowchart of the literature research according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA).
After application of the inclusion and exclusion criteria, 45 studies were finalized.

**Data extraction**

The following paper characteristics were retrieved: year of publication, journal, type of study and level of evidence. The following patient data were retrieved: number of patients, mean age, gender, previous surgery, time to follow-up, size of OLT, treatment method, concomitant surgery and clinical scoring system used. Preoperative clinical scores and results at last follow-up were extracted.

The most often reported outcome score was the American Orthopaedic Foot and Ankle Society (AOFAS) score (33 papers out of 45). Twenty-six of these 33 papers also included the s.d., the 95% CI or reported the scores for each included patient; subsequently, these studies could be used for quantitative analysis. The second most often reported score was the Visual Analogue Scale (VAS) for pain. Twenty-five papers included the VAS for pain, theretofrom 20 papers included the s.d. As less than 50% of all 45 papers included the VAS with s.d., VAS was not included in the quantitative analysis.

**Operative techniques**

Treatment strategies were divided into the following three main groups: BMS, cartilage implantation and grafts. BMS was further subdivided into three subgroups: (i) BMS alone, (ii) BMS with additional therapies such as the application of bone marrow aspirate, hyaluronic acid or special scaffolds and (iii) AMIC. Cartilage implantation was subdivided into (i) ACI and (ii) MACI. The grafts were subdivided into (i) OATS, (ii) autograft of bone such as iliac crest and (iii) allograft (Fig. 2).

**Statistical analysis**

Clinical scores preoperative and at latest follow-up, age and gender of patients as well as size of the lesion were analyzed for each included study. Additionally, data from different studies describing the results of similar treatment groups using analogous scores were pooled. 95% CI was calculated using the following formula: mean value ± 1.96 × s.d./√(number of patients). The age of patients was compared between the treatment groups using one-way Anova. The size of lesions in patients was compared between the treatment groups using Student’s t-test. Pearson’s chi square was used to compare gender between the treatment groups.

Clinical scores, age and size of the lesion were correlated using Pearson’s correlation. A value of R > 0.7 is considered a strong correlation, 0.4–0.7 a moderate correlation and < 0.4 a weak correlation. Twenty-six papers included the AOFAS score preoperative and at follow-up and s.d. at both time points. Of these 26 papers, 4 papers presented the scores for 2 different treatment methods, leading to a total of 30 patient groups available for analysis. A forest plot including the AOFAS score preoperative and at follow-up per separate study as well as the pooled results of each treatment group was conducted.

![Flowchart of surgical techniques](image)

**Figure 2**

Flowchart of the operative techniques described in the included papers. Four papers included ≥10 patients in more than one treatment group. BMS, bone marrow stimulation; AMIC, autologous matrix-induced chondrogenesis; ACI, autologous chondrocyte implantation; MACI, matrix-induced ACI; OATS, osteochondral autologous transplantation surgery; +add. therapies, with additional therapies.
| Operation technique/ reference | Patients, n | OLT size, cm² | Age, years | Before FUP | AT FUP | Other scores |
|-------------------------------|------------|--------------|-----------|-----------|--------|--------------|
| Bone marrow stimulation | 36 | 32 | 39.0 | 60 | 35.4 | 1.3 |
| Sawaia & Eaton (13) | 45 | 40.0 | 35.5 | 27 | 21.0 | 1.3 |
| Becker et al. (14) | 24 | 25.0 | 30.6 | 100 | 60.1 | 9.2 |
| De Lima et al. (15) | 36 | 39.0 | 60.4 | 76.1 | 7.1 |
| Venticinque et al. (16) | 93 | 32.6 | 41.0 | 118 | 71.0 | 0.7 |
| Van Eekeren et al. (17) | 28 | 47.4 | 11.0 | 49 | 92.1 | 0.7 |
| Gao et al. (18) | 52 | 39.7 | 58.2 | 36 | 71.1 | 0.6 |
| Murphy et al. (19) | 52 | 39.7 | 58.2 | 36 | 71.1 | 0.6 |
| Zhang et al. (20) | 156 | 15.4 | 0.1 | 30 | 71.0 | 0.6 |
| Lamberts et al. (22) | 60 | 39.0 | 109 | 24 | 69.3 | 0.9 |
| Bo et al. (23) | 23 | 39.0 | 0.9 | 24 | 69.3 | 0.9 |
| Bone marrow stimulation with additional therapy | 32 | 30.6 | 1.3 | 46 | 69.3 | 0.6 |
| Amin et al. (24) | 12 | 38.6 | 1.0 | 46 | 69.3 | 0.6 |
| Gao et al. (25) | 41 | 38.4 | 0.4 | 46 | 69.3 | 0.6 |
| Shimoji et al. (26) | 43 | 34.6 | 0.6 | 46 | 69.3 | 0.6 |
| Murthy et al. (27) | 22 | 35.0 | 0.9 | 46 | 69.3 | 0.6 |
| Akhavan et al. (28) | 22 | 35.0 | 0.9 | 46 | 69.3 | 0.6 |
| Alberga et al. (29) | 32 | 38.0 | 1.3 | 46 | 69.3 | 0.6 |
| Autologous osteochondral transplantation surgery | 32 | 38.0 | 1.3 | 46 | 69.3 | 0.6 |
| Worrall et al. (30) | 31 | 35.0 | 1.3 | 46 | 69.3 | 0.6 |
| D’Amore et al. (31) | 32 | 38.0 | 1.3 | 46 | 69.3 | 0.6 |
| Kanatli et al. (32) | 16 | 32.4 | 1.3 | 36 | 69.3 | 0.6 |
| Becker et al. (33) | 23 | 35.6 | 3.4 | 34 | 69.3 | 0.6 |
| Gallina et al. (34) | 23 | 35.6 | 3.4 | 34 | 69.3 | 0.6 |
| Autologous chondrocyte implantation | 56 | 30.6 | 2.5 | 46 | 69.3 | 0.6 |
| Barms et al. (35) | 48 | 28.5 | 2.0 | 46 | 69.3 | 0.6 |
| Ghezzi et al. (36) | 56 | 30.6 | 2.5 | 46 | 69.3 | 0.6 |
| Layton et al. (37) | 28 | 35.0 | 1.3 | 46 | 69.3 | 0.6 |
| Ghezzi et al. (38) | 28 | 35.0 | 1.3 | 46 | 69.3 | 0.6 |
| Bedi et al. (39) | 11 | 36.0 | 2.0 | 46 | 69.3 | 0.6 |
| Matrix-induced autologous chondrocyte implantation | 60 | 34.9 | 1.5 | 46 | 69.3 | 0.6 |
| Giza et al. (40) | 10 | 40.2 | 1.2 | 34 | 69.3 | 0.6 |
| Neher et al. (41) | 13 | 28.0 | 1.5 | 34 | 69.3 | 0.6 |
| Osteochondral autologous transplantation surgery | 40 | 35.6 | 2.0 | 46 | 69.3 | 0.6 |
| Lenigk et al. (42) | 36 | 35.6 | 2.0 | 46 | 69.3 | 0.6 |
| Harper et al. (43) | 35 | 30.6 | 1.3 | 34 | 69.3 | 0.6 |
| Kreuz et al. (44) | 24 | 35.0 | 1.3 | 34 | 69.3 | 0.6 |
| Goldie et al. (45) | 24 | 35.0 | 1.3 | 34 | 69.3 | 0.6 |
| Israel et al. (46) | 26 | 34.6 | 1.3 | 34 | 69.3 | 0.6 |
| Guerre et al. (47) | 32 | 31.6 | 1.3 | 34 | 69.3 | 0.6 |
| Parte et al. (48) | 46 | 34.1 | 1.3 | 34 | 69.3 | 0.6 |
| Shimozono et al. (49) | 35 | 30.6 | 1.3 | 34 | 69.3 | 0.6 |
Results

Characteristics of the patients

The 45 assessed studies reported the outcome of total 1695 patients (Table 1). The mean age at time of surgery was 35.4 years old, and 63% were male. Thirty-two studies reported the size of the lesion with a mean size of 1.4 cm². Fifteen studies assessed only patients with no previous surgery of the OLT, 6 studies assessed only revisions and 22 studies included both or did not declare it.

Quality of evidence

This review included one RCT, 12 prospective and 32 retrospective cohort studies. Thirty-four studies were classified as level 4 based on the criteria for level of evidence published by the Center for Evidence-Based Medicine (12). In recent years, the number of published studies meeting the inclusion criteria rose (Fig. 3).

Operative techniques

The most often reported operative technique was BMS alone with 11 papers including 576 patients (13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23). More than half of the patients (996/total 1695 patients) received BMS alone, BMS with an additional therapy (18, 19, 23, 24, 25, 26, 27) or AMIC (28, 29, 30, 31, 32).

BMS alone and BMS with an additional therapy were used in smaller lesions (0.88 cm² and 0.86 cm², respectively) than the other therapies (1.86 cm², P < 0.001). Figure 2

The biggest lesions (mean 2.13 cm²) were treated with ACI (33, 34, 35, 36, 37, 38). ACI was also used in youngest patient group (mean 31.5 years old), and allograft (39, 40, 41, 42) was implanted in the oldest patients with an average age of nearly 40 years. However, there was no statistical difference in age between the treatment groups (P=0.092). Three studies reported the outcome of 38 patients after MACI (43, 44, 45), 8 studies included 322 patients with OATS (46, 47, 48, 49, 50, 51, 52, 53) and 5 studies used autograft in 82 patients (13, 54, 55, 56, 57).

BMS was mostly used on primary OLT. Cartilage implantation techniques and grafts were mainly published in revision cases or mixed groups.

In 15 studies (33%), concomitant surgeries addressing an instability or deformity were conducted if necessary. In six studies, patients with additional surgeries other than the procedure for the OLT were excluded. In ten studies, patients with an instability were excluded; however, it is not specified if all patients with additional surgeries were excluded. The remaining 14 papers did not mention if additional surgeries were conducted and the authors did not reply to repeated inquiries.
Outcome scores

The most often reported outcome score was the AOFAS score. In Figure 4A and B, a total of 16 clinical scores have been published (Table 1).

There is a strong inverse correlation between the preoperative AOFAS score and the change in the AOFAS score ($R = -0.849$, $P < 0.001$) (Figure 5). There is a moderate correlation between the preoperative AOFAS score and AOFAS score at follow-up ($R = 0.421$, $P = 0.008$). Preoperative size of the cartilage lesion correlates with preoperative AOFAS scores ($R = -0.634$, $P = 0.001$) and with change in AOFAS score ($R = 0.656$, $P < 0.001$) but not with AOFAS score at follow-up.

Age of the patients at the time of surgery did not correlate with preoperative AOFAS score or change of AOFAS score, but there was a weak inverse correlation with AOFAS score at the time of follow-up ($R = -0.335$, $P = 0.046$).

Discussion

This systematic review showed a correlation of the preoperative AOFAS score with the increase of the score as well as with the outcome score. This indicates that a group of patients with inferior preoperative scores will profit more by having a bigger increase in clinical scores
but will not reach the same level 2 years postoperatively as a group of patients with higher preoperative scores.

When focusing on the size of the lesion, patients with a bigger lesion had inferior preoperative AOFAS scores, profited more and reached similar levels at follow-up as patients with a smaller lesion.

In the literature, inferior outcome in bigger lesions was found after BMS. The proposed cut off point was set at 1.07–1.5 cm² for the indication of BMS in OLT (58, 59). In the papers included in this review, BMS was used for smaller, mainly primary lesions with a mean size below 1 cm². Considering all the papers, we found no correlation between lesion size and outcome. However, patients with a bigger lesion did suffer more preoperatively and did profit more from the operation. This implies that patients with bigger and more symptomatic lesions are not too late for treatment but will show the most improvement after surgery, at least not up to a size of 200 mm² as reported in the literature included in this review. While BMS is proposed to be reserved for smaller lesions, other surgical techniques have been proven successful also in bigger lesions. The future however will show which technique will become the most accepted for OLTs over 1–1.5 cm².

The inferior outcome in older patients after BMS and AMIC was published corresponding to the findings in this review with a weak inverse correlation between age and outcome scores (14, 29). In one-third of the studies, concomitant surgeries addressing an instability or deformity were conducted. In our opinion, in patients with an underlying cause for the OLT, the therapy of this cause is essential for the successful treatment of the OLT.

The limitations of a systematic review include publication bias and selective reporting. Most papers in this review were of low methodological quality, underlining once more the necessity for more sufficiently powered randomized studies with extended follow-up times in future research. To diminish poorly conducted studies, strict inclusion criteria were applied, such as a minimum follow-up of 24 months, minimum age of 16 years old and a minimal count of ten patients included in the follow-up. A second limitation is that only papers in English were included. Further, complication ratios and revision rate were rarely stated and subsequently could not be analyzed.

Due to the observed heterogeneity of the patient population (e.g. level of the preoperative scores and size of the lesion), variety in the outcome assessment and incomplete data publication, the conduction of a meta-analysis regarding the outcome after different treatment options was not possible. In future research, a validated score for the OLT needs to be established in order to increase the homogeneity and uniformity in outcome assessment and evaluation of the results. The increase in publications on OLT in recent years shows the current importance of the topic.

**Conclusion**

In this systematic review, we found that patients with bigger and more symptomatic OLTs profited the most from surgery. BMS was the most often reported operative technique and was used for smaller, mainly primary lesions with a mean lesion size below 1 cm². Direct comparison of the outcome between the different treatment groups was not possible due to the heterogeneity of the patient population.

**ICMJE Conflict of Interest Statement**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the work reported here.

**Funding Statement**

The funding for this research was from the Department of Orthopaedic Surgery and Traumatology, Inselspital, Bern University Hospital, University of Bern, Switzerland.

**References**

1. D’Ambrosi R, Maccario C, Serra N, Ursino C & Usuelli FG. Relationship between symptomatic osteochondral lesions of the talus and quality of life, body mass index, age, size and anatomic location. *Foot and Ankle Surgery* 2018 24 365–372. (https://doi.org/10.1016/j.fas.2017.04.011)

2. Verhagen RA, Struijs PA, Bossuyt PM & van Dijk CN. Systematic review of treatment strategies for osteochondral defects of the talus dome. *Foot and Ankle Clinics* 2003 8 233–242, viii–ix. (https://doi.org/10.1016/s1083-7515(02)00064-5)

3. Shearer C, Loomer R & Clement D. Nonoperatively managed stage 5 osteochondral talus lesions. *Foot and Ankle International* 2002 23 651–654. (https://doi.org/10.1177/107110070202300712)
of osteochondral talar defects: a 5- to 24-year follow-up study. Knee Surgery, Sports Traumatology, Arthroscopy 2016 24 1311–1315. (https://doi.org/10.1007/s00167-016-3992-6)

18. Gao F, Chen N, Sun W, Wang B, Shi Z, Cheng L, Li Z & Guo W. Combined therapy with shock wave and retrograde bone marrow-derived cell transplantation for osteochondral lesions of the talus. Scientific Reports 2017 7 2106. (https://doi.org/10.1038/s41598-017-02378-9)

19. Murphy EP, McGoldrick NP, Curtin M & Kearsn SR. A prospective evaluation of bone marrow aspirate concentrate and microfracture in the treatment of osteochondral lesions of the talus. Foot and Ankle Surgery 2019 25 441–448. (https://doi.org/10.1016/j.fas.2018.02.011)

20. Wang C, Kang MW & Kim HN. Arthroscopic treatment of osteochondral lesion of the talus in a suspended position with the patient in a prone position. Foot and Ankle International 2019 40 811–817. (https://doi.org/10.1177/1071100719839697)

21. Choi SW, Lee GW & Lee KB. Arthroscopic microfracture for osteochondral lesions of the talus: functional outcomes at a mean of 6.7 years in 165 consecutive ankles. American Journal of Sports Medicine 2020 48 153–158. (https://doi.org/10.1177/0363546519887957)

22. Lambers KTA, Dahmen J, Altink JN, Reilingh ML, van Bergen CJA & Kerkhoffs GMJJ. Bone marrow stimulation for talar osteochondral lesions at long-term follow-up shows a high sports participation though a decrease in clinical outcomes over time. Knee Surgery, Sports Traumatology, Arthroscopy 2021 29 1562–1569. (https://doi.org/10.1016/j.kjsea.2020.06250-8)

23. Lee YK, Young KW, Kim JS, Lee HS, Cho WJ & Kim HN. Arthroscopic microfracture with autologous augmentation for osteochonral lesion of the talus: a multicenter randomized controlled trial. BMC Musculoskeletal Disorders 2020 21 716. (https://doi.org/10.1186/s12891-020-03730-3)

24. Sadlik B, Kolodziej L, Blasiak A, Szymczak M & Warchal B. Biological reconstruction of large osteochondral lesions of the talar dome with a modified ‘sandwich’ technique-midterm results. Foot and Ankle Surgery 2017 23 290–295. (https://doi.org/10.1016/j.fas.2016.09.001)

25. Shimozono Y, Hurley ET, Yasui Y, Deyor TW & Kennedy JG. The presence and degree of bone marrow edema influence midterm clinical outcomes after microfracture for osteochondral lesions of the talus. American Journal of Sports Medicine 2018 46 2503–2508. (https://doi.org/10.1177/0363546518782701)

26. Akmese R, Ertan MB & Kocaoglu H. Comparison of chitosan-based liquid scaffold and hyaluronic acid-based soft scaffold for treatment of talar osteochondral lesions. Foot and Ankle International 2020 41 1240–1248. (https://doi.org/10.1177/1071100720937662)

27. Di Cave E, Versari P, Scarrota F, Luzon D & Marcellini L. Biphasic bioresorbable scaffold (TruFit Plug(R)) for the treatment of osteochondral lesions of talus: 6- to 8-year follow-up. Foot 2017 33 48–52. (https://doi.org/10.1016/j.foot.2017.05.005)

28. Wiewiorski M, Werner L, Paul J, Anderson AE, Barg A & Valderrabano V. Sports activity after reconstruction of osteochondral lesions of the talus with autologous bone grafts and autologous matrix-induced chondrogenesis. American Journal of Sports Medicine 2016 44 2651–2658. (https://doi.org/10.1177/0363546516659643)

29. D’Ambrosi R, Macarcao C, Serra N, Liuni F & Uselli FG. Osteochondral lesions of the talus and autologous matrix-induced chondrogenesis: is age a negative predictor outcome? Arthroscopy: The Journal of Arthroscopic and Related Surgery 2017 33 428–435. (https://doi.org/10.1016/j.arthro.2016.09.030)

30. Becher C, Malahias MA, Ali MM, Maffulli N & Thermann H. Arthroscopic microfracture vs. arthroscopic autologous matrix-induced chondrogenesis for the treatment
of articular cartilage defects of the talus. Knee Surgery, Sports Traumatology, Arthroscopy 2019 27 2731–2736. (https://doi.org/10.1007/s00167-018-5278-7)

31. Gallia M, Duensing I, Kahn TL & Barg A. Open reconstruction with autologous spongioa grafts and matrix-induced chondrogenesis for osteochondral lesions of the talus can be performed without medial malleolar osteotomy. Knee Surgery, Sports Traumatology, Arthroscopy 2019 27 2789–2795. (https://doi.org/10.1007/s00167-018-5063-7)

32. Kanatli U, Eren A, Eren TK, Vural A, Geylan DE & Oner AY. Single-step arthroscopic repair with cell-free polymer-based scaffold in osteochondral lesions of the talus: clinical and radiological results. Arthroscopy: The Journal of Arthroscopic and Related Surgery 2017 33 1718–1726. (https://doi.org/10.1016/j.arthro.2017.06.011)

33. Baums MH, Heidrich G, Schultz W, Steckel H, Kahl E & Klinger HM. Autologous chondrocyte transplantation for treating cartilage defects of the talus. Journal of Bone and Joint Surgery: American Volume 2006 88 303–308. (https://doi.org/10.2106/JBJS.E.00033)

34. Giannini S, Buda R, Vannini F, Cavallo M & Grigolo B. One-step bone marrow-derived cell transplantation in talar osteochondral lesions. Clinical Orthopedics and Related Research 2009 467 3307–3320. (https://doi.org/10.1007/s11999-009-0885-8)

35. Giannini S, Buda R, Cavallo M, Ruffilli A, Cenacchi A, Cavallo C & Vannini F. Cartilage repair evolution in posttraumatic osteochondral lesions of the talus: from open field autologous chondrocyte to bone-marrow-derived cells transplantation. Injury 2010 41 1196–1203. (https://doi.org/10.1016/j.injury.2010.09.028)

36. Lee DH, Lee KB, Jung ST, Seon JK, Kim MS & Sung IH. Comparison of early versus delayed weightbearing outcomes after microfracture for small to midsize osteochondral lesions of the talus. American Journal of Sports Medicine 2012 40 2023–2028. (https://doi.org/10.1177/0363546512455536)

37. Kwak SK, Kern BS, Ferkel RD, Chan KW, Kasraei S & Applegate GR. Autologous chondrocyte implantation of the ankle: 2- to 10-year results. American Journal of Sports Medicine 2014 42 2156–2164. (https://doi.org/10.1177/0363546514504587)

38. Puddu L, Altamore F, Santandrea A, Mercurio D, Caggiari G, Della Sala S, Marinetto A, Tessarolo F, Rigoni M, Manunta AF, et al. Surgical treatment of talar osteochondral lesions with micro-fractures, mesenchymal cells grafting on membrane, or allograft: mid-term clinical and magnetic resonance assessment. Journal of Orthopaedics 2020 21 416–420. (https://doi.org/10.1016/j.jor.2020.08.012)

39. Raikin SM. Fresh osteochondral allografts for large-volume cystic osteochondral defects of the talus. Journal of Bone and Joint Surgery: American Volume 2009 91 2818–2826. (https://doi.org/10.1177/0363546509345205)

40. Gortz S, De Young AJ & Bugbee WD. Fresh osteochondral allografting for osteochondral lesions of the talus. Foot and Ankle International 2010 31 283–290. (https://doi.org/10.3113/FAI.2010.0283)

41. Berlet GC, Hyer CF, Philbin TM, Hartman JF & Wright ML. Does fresh osteochondral allograft transplantation of talar osteochondral defects improve function? Clinical Orthopedics and Related Research 2011 469 2356–2366. (https://doi.org/10.1007/s11999-011-1813-2)

42. Chu CH, Chen IH, Yang KC & Wang CC. Midterm results of fresh-frozen osteochondral allografting for osteochondral lesions of the talus. Foot and Ankle International 2021 42 8–16. (https://doi.org/10.1177/1071100720949861)

43. Giza E, Sullivan M, Ocel D, Lundeen G, Mitchell ME, Veris L & Walton J. Matrix-induced autologous chondrocyte implantation of talus articular defects. Foot and Ankle International 2010 31 747–753. (https://doi.org/10.3113/FAI.2010.0747)

44. Lenz CG, Tan S, Carey AL, Ang K & Schneider T. Matrix-induced autologous chondrocyte implantation (MACI) grafting for osteochondral lesions of the talus. Foot and Ankle International 2020 41 1099–1105. (https://doi.org/10.1177/1071100720935110)

45. Nehrer S, Domayer SE, Hirschfeld C, Stelzeneder D, Trattning S & Dorotka R. Matrix-associated and autologous chondrocyte transplantation in the ankle: clinical and MRI follow-up after 2 to 11 years. Cartilage 2011 2 81–91. (https://doi.org/10.1177/1947603510381095)

46. Hangedy L, Kish G, Modis L, Szerb I, Gaspar L, Dioszegi Z & Kendzik Z. Mosaplasty for the treatment of osteochondritis dissecans of the talus: two to seven year results in 36 patients. Foot and Ankle International 2001 22 552–558. (https://doi.org/10.1177/107110070102200704)

47. Kreuz PC, Steinwachs M, Erggelet C, Lahm A, Henle P & Niemeyer P. Mosaplasty with autogenous talar autograft for osteochondral lesions of the talus after failed primary arthroscopic management: a prospective study with a 4-year follow-up. American Journal of Sports Medicine 2006 34 55–63. (https://doi.org/10.1177/0363546505278299)

48. Gobbi A, Francisco RA, Lubowitz JH, Allegra F & Canata G. Osteochondral lesions of the talus: randomized controlled trial comparing chondroplasty, microfracture, and osteochondral autograft transplantation. Arthroscopy: The Journal of Arthroscopic and Related Surgery 2006 22 1085–1092. (https://doi.org/10.1016/j.arthro.2006.05.016)

49. Imhoff AB, Paul J, Ottinger B, Wortler K, Lammle L, Spang J & Hinterwimmer S. Osteochondral transplantation of the talus: long-term clinical and magnetic resonance imaging evaluation. American Journal of Sports Medicine 2011 39 1487–1493. (https://doi.org/10.1177/0363546510399276)

50. Georgiannos D, Babisina I & Badekas A. Osteochondral transplantation of autologous graft for the treatment of osteochondral lesions of talus: 5- to 7-year follow-up. Knee Surgery, Sports Traumatology, Arthroscopy 2016 24 3722–3729. (https://doi.org/10.1177/0363546516623042)

51. Gul M, Cetinkaya E, Aykut ÜS, Ozkub B, Saygili MS, Akman YE & Kabukcuoglu YS. Effect of the presence of subchondral cysts on treatment results of autologous osteochondral graft transfer in osteochondral lesions of the talus. Journal of Foot and Ankle Surgery 2016 55 1003–1006. (https://doi.org/10.1053/j.jfas.2016.05.012)

52. Park KH, Hwang Y, Han SH, Park YJ, Shim DW, Choi WJ & Lee JW. Primary versus secondary osteochondral autograft transplantation for the treatment of large osteochondral lesions of the talus. American Journal of Sports Medicine 2018 46 1389–1396. (https://doi.org/10.1177/0363546518758014)

53. Shimozono Y, Donders JCE, Yasui Y, Hurley ET, Deyer TW, Nguyen JT & Kennedy JG. Effect of the containment type on clinical outcomes in osteochondral lesions of the talus treated with autologous osteochondral transplantation. American Journal of Sports Medicine 2016 44 2096–2102. (https://doi.org/10.1177/0363546514551570)

54. Leumann A, Valderrabano V, Wiewiorski M, Barg A, Hinterrmn B & Pagenstert G. Bone periostium-covered iliac crest plug transplantation for severe osteochondral lesions of the talus: a modified mosaicplasty procedure. Knee Surgery, Sports Traumatology, Arthroscopy 2014 22 1304–1310. (https://doi.org/10.1177/0363546513483600)

55. Hu Y, Guo Q, Jiao C, Mei Y, Jiang D, Wang J & Zheng Z. Treatment of large cystic medial osteochondral lesions of the talus with autologous osteoperiosteal cylinder grafts. Arthroscopy: The Journal of Arthroscopic and Related Surgery 2013 29 1372–1379. (https://doi.org/10.1016/j.arthro.2013.05.014)
56. Hintermann B, Wagener J, Knupp M, Schweizer C & Schaefer DJ. Treatment of extended osteochondral lesions of the talus with a free vascularised bone graft from the medial condyle of the femur. *Bone and Joint Journal* 2015 97-B 1242–1249. ([https://doi.org/10.1302/0301-620X.97B12.35292](https://doi.org/10.1302/0301-620X.97B12.35292))

57. Bai L, Guan S, Liu S, You T, Xie X, Chen P & Zhang W. Clinical outcomes of osteochondral lesions of the talus with large subchondral cysts treated with osteotomy and autologous chondral grafts: minimum 2-year follow-up and second-look evaluation. *Orthopaedic Journal of Sports Medicine* 2020 8 2325967120937798. ([https://doi.org/10.1177/2325967120937798](https://doi.org/10.1177/2325967120937798))

58. Ramponi L, Yasui Y, Murawski CD, Ferkel RD, DiGiovanni CW, Kerkhoffs GMMJ, Calder JDF, Takao M, Vannini F, Choi WJ, *et al*. Lesion size is a predictor of clinical outcomes after bone marrow stimulation for osteochondral lesions of the talus: a systematic review. *American Journal of Sports Medicine* 2017 45 1698–1705. ([https://doi.org/10.1177/0363546516668292](https://doi.org/10.1177/0363546516668292))

59. Choi WJ, Park KK, Kim BS & Lee JW. Osteochondral lesion of the talus: is there a critical defect size for poor outcome? *American Journal of Sports Medicine* 2009 37 1974–1980. ([https://doi.org/10.1177/0363546509335765](https://doi.org/10.1177/0363546509335765))